Lobbying Filing Details

Total Spending

$1,940,000

Activities

4

Lobbyists

4

Gov't Entities

16

Filing Information
Filing UUID:
768f22d0-7f39-42d1-ab83-69da3a3d6488
Type:
Q3 - 3rd Quarter - Report
Period:
2021 - 3rd Quarter (July 1 - Sep 30)
Date Posted:
October 20, 2021 at 8:58 PM
Income:
$0
Expenses:
$1,940,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Daniel Bachner
Registrant
ABBVIE, INC.

Biopharmaceutical company

Washington, District of Columbia
Client
ABBVIE INC.
District of Columbia, United States of America
Lobbying Activities (4)
Activity 1
Copyright/Patent/Trademark

H.R.2891, Preserve Access to Affordable Generics and Biosimilars Act - all
H.R.2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 - all
H.R.2883, Stop Stalling Access to Affordable Medications - all
H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - all
Patent litigation reform issues and issues related to post-grant proceedings at the USPTO
Value of intellectual property

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Treasury, Dept of
Activity 2
Health Issues

H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act - all
H.R. 19, Lower Costs, More Cures Act - all
H.R. 5260, Reduced Costs and Continued Cures Act - all
S. 2164, Lower Costs, More Cures Act of 2021 - all
Drug cost and pricing policy issues
Patient affordability issues
Policy proposals relating to clinical trial diversity
Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021 & 2022; Notice Requirement for Non-Federal Governmental Plans proposed rule

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Treasury, Dept of
Activity 3
Medicare/Medicaid

H.R. 3684, Infrastructure Investment and Jobs Act - provisions related to Medicare Part B vial size refund policy
Policy Proposals related to Medicare Part D and patient cost-sharing
Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F)

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Treasury, Dept of
Activity 4
Taxation/Internal Revenue Code

H.R.5376, Build Back Better Act - provisions related to corporate taxes, Medicare, and prescription drug pricing
Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation
Policy proposals relating to economic activity in Puerto Rico
International tax issues, including OECD tax framework

Lobbyists (4)
  • STEPHEN SCANGO
  • DANIEL BACHNER
  • DORCAS ADEKUNLE
  • CRYSTAL RILEY
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Treasury, Dept of

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.